Zepbound (Tirzepatide) Patent Expiration, LOE Window & CMS Spending

Zepbound (Tirzepatide) by Eli Lilly: FDA Orange Book core substance LOE 2036-05-13 (last listed 2039-07-22), 0 AB generics, $277.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEli Lilly
FDA Application & PathwayN217806 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-05-13
Last Listed Patent or Exclusivity Date2039-07-22
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$277.8M
2024 Medicare Part D Spend$387K
2024 Medicaid Spend$277.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.